Parameter
| Biomarker | CKD273 panel | Full name | Chronic Kidney Disease 273 urinary peptide biomarker panel | Molecular Type | Protein（Specific peptides) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Early screening, risk stratification | ||
| Disease | Chronic Kidney Disease (CKD) | Disease Subtypes | / | ||
| Organ | Kidney | Test Sample / Technology Platform | Urine ( mass spectrometry, proteomics detection ) | ||
| Pathobiological Mechanisms | It is composed of 273 urinary peptides, reflecting CKD-related molecular network abnormalities. | ||||
| Clinical Availability Status | Clinically available ( in vitro diagnostic reagents ) | ||||
| Notes and Dynamics | Prognostic value in predicting the risk of progression to microalbuminuria in patients with type 2 diabetes has been endorsed by the U.S. FDA and is being used for patient stratification in a multicenter PRIORITY trial. | ||||